10x Genomics Announces Preliminary Financial Results for 2025
10x Genomics, Inc. (NASDAQ: TXG), a leader in single-cell and spatial biology, recently revealed preliminary financial results for its fourth quarter and full year ended December 31, 2025. These results highlight the company’s ongoing commitment to innovation and excellence in the biotechnology sector.
Preliminary Results for Q4 2025
The results for the fourth quarter of 2025 have shown promising figures. The revenue for this quarter reached approximately $166 million, reflecting an 11% sequential growth and 1% growth compared to the same period in the previous year.
Instruments Revenue
Within this revenue figure, instruments revenue reached around $15.5 million. This marks a 29% increase sequentially; however, it illustrates a 36% decrease compared to the prior year’s corresponding quarter. This breakdown indicates an increase in sales for Single Cell instruments but a decrease in Spatial instruments, which highlights market trends in these technology areas.
Consumables Revenue Growth
On a more positive note, consumables revenue amounted to approximately $141.7 million. This reflects an 11% increase sequentially and a 6% increase over the previous year’s comparable quarter. The breakdown shows that Single Cell consumables brought in $100.8 million, marking a 9% sequential growth and a steady 3% year-over-year growth. Spatial consumables revenue also grew, achieving $41 million, a 16% increase sequentially and 14% compared to the previous year.
Full Year Financial Overview for 2025
For the full year 2025, 10x Genomics reported revenue of approximately $642.8 million. If excluding $44.1 million associated with patent litigation settlements during the first and second quarters, the adjusted revenue stands around $598.7 million, exhibiting a 2% decrease from the previous year.
Instruments and Services Revenue Metrics
Instruments revenue for the full year was about $56.8 million, showing a notable decrease of 39% from the prior year due to industry shifts. Single Cell instruments accounted for $22.7 million, which is a 36% decline year-over-year, while Spatial instruments generated $34.1 million, a 41% drop from the previous year.
Progress in Consumables and Services
In contrast, consumables revenue saw an increase to approximately $507.2 million, representing a 3% growth compared to the previous year. Notably, Single Cell consumables amounted to $363.2 million, which is a slight decrease of 2% from the prior year. However, Spatial consumables represented a significant growth, accruing $144 million, which is a 19% increase year-over-year.
Looking Ahead and Company Strategy
Serge Saxonov, Co-founder and CEO of 10x Genomics, expressed pride in the team’s resilience throughout 2025. He noted that despite a challenging macro environment, the company successfully strengthened customer partnerships, advanced its product roadmap, and maintained robust operational discipline. Saxonov believes that these efforts have solidified the company’s balance sheet for future endeavors.
Upcoming Events and Company Initiatives
10x Genomics is gearing up for the 44th Annual J.P. Morgan Healthcare Conference, where the company will provide further insights into its operations and strategic direction. Interested investors can tune into a live webcast of this presentation, showcasing the company’s ongoing projects and future objectives.
About 10x Genomics
10x Genomics is dedicated to enhancing life science through innovative products aimed at advancing the understanding of biology and improving human health. The company’s robust offerings encompass integrated solutions that deliver instruments, consumables, and software designed for single-cell and spatial biology. Through its cutting-edge technology, 10x Genomics continues to empower researchers in various biopharmaceutical fields, including oncology, immunology, and neuroscience.
Frequently Asked Questions
What were 10x Genomics' preliminary financial results for 2025?
10x Genomics reported approximately $166 million in revenue for Q4 2025 and around $642.8 million for the full year 2025, with adjusted figures reflecting a 2% decrease.
How did consumables revenue perform in 2025?
Consumables revenue totaled approximately $507.2 million for the full year, representing a growth of 3% year-over-year.
What challenges did 10x Genomics face during 2025?
The macroeconomic environment posed challenges, yet the company managed to strengthen customer relationships and operational efficiencies.
What is the significance of the upcoming J.P. Morgan Healthcare Conference?
This conference provides 10x Genomics an opportunity to share insights and future strategies with investors and industry stakeholders.
What are the company’s plans for future growth?
10x Genomics is focused on innovation, product development, and expanding its market presence to enhance its impact within the biotechnology industry.
